Cipla partners with S&D Pharma to tap Czech Republic and Slovakia
Under the collaboration, Cipla will be driving its respiratory product portfolio in both Czech Republic and Slovakia
BS B2B Bureau B2B Connect | Mumbai
Under the collaboration, Cipla will be driving its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head. S&D Pharma will physically distribute all products, including respiratory products, and this portfolio will increase over the next few years.
Frank Pieters, Head Cipla Europe, said, “We are excited to partner with S&D Pharma and believe that this collaboration will enable us to drive access in the Czech Republic and Slovakia across therapy areas in the coming years.”
Also Read
In the near future, once the necessary regulatory and reimbursement approvals are in place, the Salmeterol-Fluticasone fixed combination will be launched in both markets under the name Fullhale. “With Fullhale we will offer in Czech Republic and Slovakia an alternative which is effective and efficient and therefore brings many advantages into a market which suffers from limited resources,” Cipla said in a pess release.
Apart from Croatia where the combination is already available under the name Duohal, Cipla recently launched the product in Germany and Sweden. In Germany, the product is distributed under the name Serroflo, whereas in Sweden the combination is launched as Salmeterol/Fluticasone Cipla.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Sep 09 2014 | 4:04 PM IST